For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Bluebird Bio, Inc.

USPTO Granted Patents = 34

% Expired Patents = 2.9

CIPO Patents = 2

EPO Patents = 14

Forward Citations = 315

Loading Chart...

Loading Chart...

26 inventors (with patents filed for the assignee):

Kevin Friedman (8 out of 21 patents)

Richard Morgan (7 out of 14 patents)

Karen Westerman (6 out of 10 patents)

4. Jordan Jarjour (5 out of 23 patents)

5. Olivier Negre (5 out of 5 patents)

6. Philippe Louis Leboulch (5 out of 5 patents)

7. Robert Pawliuk (5 out of 5 patents)

8. Garrett Collins Heffner (4 out of 4 patents)

9. Abraham Isaac Bassan (4 out of 4 patents)

10. Gabor Veres (4 out of 6 patents)

11. Alexander Astrakhan (3 out of 9 patents)

12. Michael Certo (3 out of 5 patents)

13. Maria Joann Denaro (3 out of 3 patents)

14. Mitchell Howard Finer (3 out of 3 patents)

15. Julian Down (3 out of 3 patents)

34 patents: Sort by Forward Citations

1. 12686711 - DARIC INTERLEUKIN RECEPTORS (2026-07-21),

2. 12234476 - VCN enhancer compositions and methods of using the same (2025-02-25),

3. 12234296 - Sickled beta globin antibodies (2025-02-25),

4. 11834668 - Compounds for improved viral transduction (2023-12-05),

5. 11701435 - Therapeutic retroviral vectors for gene therapy (2023-07-18),

6. 11535681 - Sickled beta globin antibodies (2022-12-27),

7. 11326183 - VCN enhancer compositions and methods of using the same (2022-05-10),

8. 11261441 - Vectors and compositions for treating hemoglobinopathies (2022-03-01),

9. 11020466 - BCMA chimeric antigen receptors (2021-06-01),

10. 10927367 - CBLB endonuclease variants, compositions, and methods of use (2021-02-23),

11. 10907177 - Compounds for improved viral transduction (2021-02-02),

12. 10793843 - CBLB endonuclease variants, compositions, and methods of use (2020-10-06),

13. 10774343 - MND promoter chimeric antigen receptors (2020-09-15),

14. 10646558 - BCMA chimeric antigen receptors (2020-05-12),

15. 10639359 - BCMA chimeric antigen receptors (2020-05-05),

bluebird bio is a biotechnology company that develops gene therapies for severe genetic diseases. The company's pipeline includes potential treatments for diseases such as beta-thalassemia, sickle cell disease, cerebral adrenoleukodystrophy, and multiple myeloma. Their innovative gene therapy platform focuses on modifying a patient's own cells to address the underlying cause of the disease. Through extensive research and clinical trials, bluebird bio aims to transform the lives of patients and families affected by these genetic diseases.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

Bluebird Bio, Inc.

34 Patents

#83 in Cambridge, MA

#600 in Massachusetts

#9,984 in US

#19,575 in the World

Cambridge, MA, United States of America

Bluebird Bio, Inc.

Forward Citations = 315

26 inventors:

Kevin Friedman (8 out of 21 patents)

Richard Morgan (7 out of 14 patents)

Karen Westerman (6 out of 10 patents)

4. Jordan Jarjour (5 out of 23 patents)

5. Olivier Negre (5 out of 5 patents)

Please report any incorrect information to [email protected]

Loading…